Chart of the Week: Celgene Poised to Dominate Personalized Medicine?

In our Charts of the Week over the last several weeks we have been analyzing the use of unique biomarkers by pharmaceutical companies.  We are extending that analysis today with a look at the biomarker discovery activity of pharma companies as compared with the number of unique biomarkers they are ...

Chart of the Week: Over 150 Companion Diagnostic Biomarkers in Current Development

We have recently been focusing on the growth in the use of biomarkers in clinical trials, and today pulled data from BiomarkerBase to examine the growth in the number of unique biomarkers that are being used in the inclusion/exclusion criteria of active clinical trials.

Chart of the Week: Over 700 Unique Biomarkers in 2015 Clinical Trials

Last week our chart of the week was a look at the total number of clinical trials started annually that include biomarkers, with a projection out to 2020.  The hockey stick shape of the growth rate was striking, so much so that we decided to follow-up and ask the question: are there actually new ...

Chart of the Week: Huge Growth in Clinical Trials Involving Biomarkers

This week's chart is an analysis of the number of clinical trials started each year in which biomarkers are being measured.  The growth rate surprised even us, and we are projecting that five years from now, almost 2,500 clinical trials involving biomarkers will be started annually.

Unique Biomarkers Are Associated With More Drug Approvals

In our Chart of the Week post from last week we presented an analysis of the number of unique biomarkers being used by leading drug developers in their clinical trials (unique biomarkers being defined as those that aren't being used by any other companies).

News From the Personalized Medicine World Conference: Platforms Dominate

by John Audette | Feb 02, 2016 | personalized medicine

I was in Silicon Valley last week for the 10th annual Personalized Medicine World Conference, and the primary themes were quite similar to last year's event. On the research side, more phenotypes and data sharing remain the key limiting factors to faster growth in personalized/precision medicine. ...




Pharmacovigilance and Safety Biomarkers

New Call-to-action

Subscribe for Updates

Download our Free IVD Trends Report